Undervalued Industry Leader with a 5% Yield

This stock lacks the revenue growth potential of some biotech peers, but it also lacks the cash burn and often binary uncertainty. It bears closer resemblance to a traditional pharma stock with biotech characteristics. Given the company’s industry leading position, solid fundamentals and attractive stock valuation, we view it as a preferable alternative to traditional drug stocks. It offers lower-risk exposure to biotech innovation as an added bonus.

Not a Member Yet?

You need a Gold Membership or higher to view the content on this page.
Start Your Gold Membership Today | Members Log In Here

Photo Credit: TheFemGeek (Flickr)

1 Comment

  • Patrick

    May 8, 2017

    Will you offer the Scottrade discount to TD Ameritrade account holders since they are owned by the same parent?

Leave A Response

* Denotes Required Field